OR WAIT null SECS
© 2023 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
Sumitovant Biopharma has completed its acquisition of Myovant Sciences in an all-cash deal worth $1.7 billion, with Myovant being delisted from the New York Stock Exchange and its shares no longer publicly traded.
Sumitovant Biopharma Ltd. and Myovant Sciences Ltd. announced that Sumitovant has successfully completed its acquisition of Myovant originally announced October 23, 2022.
"We are excited to have officially completed our acquisition of Myovant and look forward to working together to address unmet needs in women's health and prostate cancer," said Myrtle Potter, CEO of Sumitovant. "By combining our unique expertise, platforms and resources, we will be better positioned to drive the growth of Myovant's products and accelerate the development of our robust combined pipeline."